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A b s t r a c t  
Biosimilars are to Biologic products what generic drugs are to chemical products, a more affordable 
solution to the increasing drug pricing without sacrificing the quality of the treatment. There is much 
debate in the health care industry as to whether Biosimilars will deliver on the same success 
achieved by the generic products, which can amount to up to 80% in some cases.   It is my view 
though that Biosimilars provide a viable path to cost reduction, quality improvement and affordable 
accessibility to medication.  In fact, the introduction of lower costs Biologics as intended by the 
Biosimilar market will force competition within the therapeutics treatment market that will both exert 
pricing pressure as well as inspire innovation in the entire ecosystem.  
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Introduction 
 
Will the Biosimilar products deliver on value and cost savings 
expectations while ensuring quality? 
By way of background, in 1984 the Drug Price Competition and 
Patent Term Restorations Act (Hatch-Waxman Act) provided an 
abbreviated pathway for drug companies to reproduce the innovator 
sponsor drug after the patent expiry period. By demonstrating 
comparability to a “brand/reference listed drug product in dosage 
form, strength, route of administration, quality and performance 
characteristics, and intended use” [FDA], by meeting the definition 
criteria, the drug manufacturer is allowed a shorter approval process 
known as Abbreviated New Drug Application (ANDA). This 
approach is effectively based on demonstrating science equivalence 
and manufacturing reproducibility, thus minimizing the more 
expensive development, clinical and non-clinical testing required for 
an innovator’s drug approval.   
The pathway derived as a byproduct of the Hatch-Waxman Act 
forged a step forward in achieving pharmaceutical drug savings as 
today more than 50% of prescription drugs are filed with generic 
products [FDA].In 2010, the Patient Protection and Affordable Care 
Act (Affordable Care Act) was signed into law to amend the Public 
Health Service Act (PHS Act). The Affordable Care Act follows the 
pathway of allowing the pharmaceutical Biologics product to be 
developed, manufactured and marketed via an abbreviated 
approval process, under the designation of Biosimilars.  This 
pathway is known as the Biologics Price Competition and Innovation 
Act (BPCI Act). 
Biosimilars are not an exact replica of the innovator product; they 
can either be ‘highly similar’ or ‘interchangeable’, unlike the generic 
products that are required to be a ‘generic copy’ of the innovator 
product.  It is the differences between the BPCI Act and Hatch-
Waxman Act that puts into question the true quality attributable to 
the Biosimilar products as a viable replacement for the branded 
Biologic products. 
Upon closer look at the BPCI Act in combination with FDA guidance 
documents on Biosimilars, we are assured that these considerations 
are reflected in the more stringent requirements when 
demonstrating Biosimilars. More specifically, the guidance 
documents ascertain the need for.  
Biosimilars to undergo both clinical and non-clinical testing prior to 
product approval, in conjunction with all international and domestic 
laws and regulations governing pharmaceutical products intended 
for human use.  
Additional controls are set in place by the United States Food and 
Drug Administration (FDA) to stipulate the necessary transparencies 
and supplemental controls throughout the Biosimilar supply chain 
process in order to ensure safe delivery of the product to patients, 
addressing some key policy issues.  For example, Biosimilar 
products will be labeled in such a way so as to differentiate between 
‘highly similar’ or ‘interchangeable’ and whether a pharmacist will be 
able to make a substitution when dispensing the medications.  The 
current provisions placed by the FDA guidance documents will 
ensure the safety and quality of Biosimilars as a mainstream 
treatment alternative in the future. 
Biosimilars are projected to introduce 20% to 30% price reductions 
(vs Biologics), unlike the whopping 80% price reductions achieved 
by some generic products.  This conservative estimate stems from 
the fact that the large molecules (Biologics and Biosimilars) 
manufacturing process is expensive and the industry, in general, is 
still in need of acquiring the necessary experience and expertise to 
streamline the processes. The BPCI Act will accelerate the 
technological competition among Biological and Biosimilar 
manufacturers in providing more robust models for the 
manufacturing process as well as the supply chain operation to 
expedite product access to market and to maintain strong market 
share.   
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Biosimilar products are intended for the treatment of chronic and 
genetic diseases such as diabetes, auto immune disorder, oncology 
and arthritis, to name a few.  The expected price reduction of 20% 
to 30% will be a considerable savings over the patients’ life 
expectancy in the United State with an aging generation diagnosed 
with chronic diseases such as arthritis and diabetes where, in some 
cases patients are depending on one or more Biologic medications. 
Mulcahy et.al, 2015; estimates the potential savings of Biologics 
due to the introduction of Biosimilars among the main classes to be 
on the order of: (a) 21% for Anti-TNF products, (b) 15% for Long-
acting insulins, (c) 13% for Monoclonal antibody antineoplastics, 
and (d) 11% for Fast-acting insulins. 
The Biosimilars market will also drive pharmaceutical innovators to 
discover new therapies to maintain a technological edge in the field, 
thus stimulating overall economic growth in the health care sector 
which constitutes approximately 40% of the US market.  It will 
provide patients with more options and access to treatment 
alternatives. 
In conclusion, the BPCI Act will serve as a catalyst in driving cost 
reduction in the Biologics therapeutic area by affording 
manufacturers, physicians, insurers and patients a menu of options 
at reduced costs. The congressional Budget Office in the US 
reported potential savings of USD 25 billion between 2008 and 
2018 through the use of Biosimilars” [Sandoz, WEB].  It will increase 
health care access by providing patients with alternative therapies in 
general and reduced biosimilar in particular, all with the assurances 
of a well-defined quality expectation set forth by documented 
guidance and regulations. 
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